Dilyan Ferdinandov

Prof. Dr. Dilyan Ferdinandov

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAdriana Georgieva Bakalova
Adriana Georgieva Bakalova
Hristo P. VarbanovHristo P. Varbanov
Hristo P. Varbanov
RBRossen Buyukliev
Rossen Buyukliev
GMGeorgi Momekov
Georgi Momekov
DFDilyan Ferdinandov
Dilyan Ferdinandov
DIDarvin Ivanov
Darvin Ivanov

1 November 2008 in Phytomedicine
Verified
Journal Article
Closed access
GMGeorgi Momekov
Georgi Momekov
DFDilyan Ferdinandov
Dilyan Ferdinandov
Dimitrina Zheleva-DimitrovaDimitrina Zheleva-Dimitrova
Dimitrina Zheleva-Dimitrova
PNParaskev Todorov Nedialkov
Paraskev Todorov Nedialkov
UGU. Girreser
U. Girreser
GKG. Kitanov
G. Kitanov

17 February 2006 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
GMGeorgi Momekov
Georgi Momekov
DFDilyan Ferdinandov
Dilyan Ferdinandov
ABAdriana Bakalova
Adriana Bakalova
Maya Margaritova ZaharievaMaya Margaritova Zaharieva
Maya Margaritova Zaharieva
SKSpiro Konstantinov
Spiro Konstantinov
MKMargarita Karaivanova
Margarita Karaivanova

1 September 2009 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
YEYavor Enchev
Yavor Enchev
DFDilyan Ferdinandov
Dilyan Ferdinandov
GKGeorgi Kounin
Georgi Kounin
EEElitsa Encheva
Elitsa Encheva
VBVentzeslav Bussarsky
Ventzeslav Bussarsky

Verified
Journal Article
Open access
PDF file
DFDilyan Ferdinandov
Dilyan Ferdinandov
VKViktor Kostov
Viktor Kostov
MHMaya Hadzhieva
Maya Hadzhieva
VSVelizar Shivarov
Velizar Shivarov
PPPeter Petrov
Peter Petrov
APAnastas Dimitrov Pashov
Anastas Dimitrov Pashov
Combining adaptive and innate immunity induction modes, the repertoire of immunoglobulin M (IgM) can reflect changes in the internal environment including malignancies. Previously, it was shown that a mimotope library reflecting the public IgM repertoire of healthy donors (IgM IgOme) can be mined for efficient probes of tumor biomarker antibody reactivities. To better explore the interpretability of this approach for IgM, solid tumor-related profiles of IgM reactivities to linear epitopes of actual tumor antigens and viral epitopes were studied. The probes were designed as oriented planar microarrays of 4526 peptide sequences (as overlapping 15-mers) derived from 24 tumor-associated antigens and 209 cancer-related B cell epitopes from 30 viral antigens. The IgM reactivity in sera from 21 patients with glioblastoma multiforme, brain metastases of other tumors, and non-tumor-bearing neurosurgery patients was thus probed in a proof-of-principle study. A graph representation of the binding data was developed, which mapped the cross-reactivity of the mixture of IgM (poly)specificities, delineating different antibody footprints in the features of the graph—neighborhoods and cliques. The reactivity graph mapped the major features of the IgM repertoire such as the magnitude of the reactivity (titer) and major cross-reactivities, which correlated with blood group reactivity, non-self recognition, and even idiotypic specificities. A correlation between an aspect of this image of the IgM IgOme, namely, small cliques reflecting rare self-reactivities and the capacity of subsets of the epitopes to separate the diagnostic groups studied was found. In this way, the graph representation helped the feature selection in its filtering step and provided reduced feature sets, which, after recursive feature elimination, produced a classifier containing 51 peptide reactivities separating the three diagnostic groups with an unexpected efficiency. Thus, IgM IgOme approaches to repertoire studies is greatly augmented when self/viral antigens are used and the data are represented as a reactivity graph. This approach is most general, and if it is applicable to tumors in immunologically privileged sites, it can be applied to any solid tumors, for instance, breast or lung cancer.

1 January 2008 in Bioinorganic Chemistry and Applications
Verified
Journal Article
Open access
PDF file
GMGeorgi Momekov
Georgi Momekov
DFDilyan Ferdinandov
Dilyan Ferdinandov
SKSpiro Konstantinov
Spiro Konstantinov
SASonja Arpadjan
Sonja Arpadjan
DTDaniela Tsekova
Daniela Tsekova
MKMargarita Karaivanova
Margarita Karaivanova
The antineoplastic potential of a stable monomeric Au(II) complex with hematoporphyrin IX (Hp), namely [Au(II)Hp-2H.], was investigated in a panel of tumor cell lines. The complex exhibits strong cytotoxicity, whereby the leukaemia‐ and lymphoma‐derived cell lines are more sensitive, with IC50 values comparable to those of the reference anticancer drug cisplatin. In contrast, the solid tumor models are more sensitive to the platinum drug. A comparative assessment of both agents against the human kidney cell line 293T has shown that [Au(II)Hp-2H.] is less cytotoxic. The gold complex induces oligonucleosomal DNA fragmentation in tumour cells following 24‐hour treatment and hence its cytotoxic effect is at least partly mediated by induction of apoptotic cell death. A prominent intracellular gold accumulation was detected after treating tumor cells with [Au(II)Hp-2H.] which shows that its putative pharmacological targets are readily accessible after a short incubation period.